Extended Data Fig. 10: The combination of Mal-LbL NPs with CPI shows tumor clearance and recovery (day 130) of pancreatic findings.
From: IL-12-releasing nanoparticles for effective immunotherapy of metastatic ovarian cancer
a-d, B6C3F1 mice inoculated with 106 HM-1-luc tumor cells on day 0 were treated on days 7 and 14 with 20 µg of IL-12 as a free cytokine or conjugated to Mal-LbL Mice were also treated with 250 µg of anti-PD1 and 100 µg of anti-CTLA4 i.p. on days 8 and 15. Mice were euthanized before tumor inoculation (healthy n = 5), prior to the first dose (day 7, n = 3 animals), on day 65 (n = 5 animals), or on day 130 (n = 4 animals). Organs were harvested and processed for histopathologic evaluation. Shown are representative images of the primary finding in the omentum/pancreasin naive mice (a), day 7 mice showing tumor, inflammation and pancreatic degeneration (b), day 65 mice showing inflammation and pancreatic degeneration (c), and day 130 mice showing recovered omentum/pancreas (d).
